STOCK TITAN

Schedule 13G/A: RA Capital, Kolchinsky, Shah Report Zero ALEC Holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Alector, Inc. Schedule 13G/A summary: This amendment reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals (Peter Kolchinsky and Rajeev Shah) each beneficially own 0 shares of Alector common stock, representing 0.0% of the class as of the reporting date. The filing lists the reporting persons' principal business address at c/o RA Capital Management, 200 Berkeley Street, Boston, MA, and states the entities are Delaware partnerships while the individuals are U.S. citizens. The reporting persons expressly disclaim status as a group and confirm the securities were not acquired to influence control of the issuer. The filing incorporates a Joint Filing Agreement by reference.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: No reported holdings; disclosure is routine and has no direct financial impact on Alector.

The Schedule 13G/A shows zero beneficial ownership by RA Capital, its healthcare fund, and named principals, indicating no current economic stake or voting influence from these filers. Because aggregate ownership is 0.0%, this filing does not alter shareholder composition, voting dynamics, or capital structure. The explicit disclaimer that the filers are not a group and the certification that shares were not acquired to influence control further support a neutral market impact. This is a transparency/housekeeping disclosure rather than a material event.

TL;DR: Governance implications are minimal; filers report no voting or dispositive power.

The document documents that neither sole nor shared voting/dispositive power exists for the reporting persons over Alector common stock. From a governance perspective, there is no change to potential activist influence or representation rights from these parties. The incorporation of a Joint Filing Agreement is procedural. Overall, the filing clarifies ownership status and confirms the absence of coordinated control efforts.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:08/14/2025
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:08/14/2025
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:08/14/2025
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:08/14/2025
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to Schedule 13G filed on December 6, 2024)

FAQ

Does RA Capital or its affiliates own shares of Alector (ALEC)?

No. The Schedule 13G/A reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah each beneficially own 0 shares, representing 0.0% of the class.

What voting or dispositive power do the reporting persons have over ALEC shares?

The filing states each reporting person has 0 sole voting power, 0 shared voting power, 0 sole dispositive power, and 0 shared dispositive power.

Do the reporting persons claim to be a group for Schedule 13G purposes?

No. The filing expressly disclaims status as a "group" for purposes of this Schedule 13G.

What address is listed for the reporting persons filing on ALEC?

The principal business address for the reporting persons is listed as c/o RA Capital Management, 200 Berkeley Street, 18th Floor, Boston, MA 02116.

Does the filing indicate any intent to influence control of Alector?

The certification states that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Alector

NASDAQ:ALEC

View ALEC Stock Overview

ALEC Rankings

ALEC Latest News

ALEC Latest SEC Filings

ALEC Stock Data

222.93M
95.26M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SOUTH SAN FRANCISCO